GB202015788D0 - Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders - Google Patents

Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Info

Publication number
GB202015788D0
GB202015788D0 GBGB2015788.9A GB202015788A GB202015788D0 GB 202015788 D0 GB202015788 D0 GB 202015788D0 GB 202015788 A GB202015788 A GB 202015788A GB 202015788 D0 GB202015788 D0 GB 202015788D0
Authority
GB
United Kingdom
Prior art keywords
depression
treatment
therapeutic agent
agent composition
cognitive impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2015788.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomed Industries Inc
Original Assignee
Biomed Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Industries Inc filed Critical Biomed Industries Inc
Publication of GB202015788D0 publication Critical patent/GB202015788D0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2015788.9A 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders Ceased GB202015788D0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671485P 2018-05-15 2018-05-15
US201862671466P 2018-05-15 2018-05-15
US201862674855P 2018-05-22 2018-05-22
PCT/US2019/032403 WO2019222339A1 (en) 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Publications (1)

Publication Number Publication Date
GB202015788D0 true GB202015788D0 (en) 2020-11-18

Family

ID=68541027

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2015788.9A Ceased GB202015788D0 (en) 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Country Status (9)

Country Link
US (3) US11090303B2 (https=)
EP (1) EP3843768A4 (https=)
JP (2) JP7699378B2 (https=)
CN (1) CN112423774A (https=)
AU (1) AU2019271189A1 (https=)
BR (1) BR112020023252A2 (https=)
GB (1) GB202015788D0 (https=)
MA (1) MA53500A (https=)
WO (1) WO2019222339A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398792A1 (en) * 2018-05-15 2024-12-05 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
EP3843768A4 (en) * 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS
GB2613460B (en) * 2020-04-20 2025-07-23 Lloyd Hung Loi Tran Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
WO2022051631A1 (en) * 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
TW202245773A (zh) * 2021-02-12 2022-12-01 紐西蘭商紐藍製藥公司 普威二氏症候群之治療
CN114582507A (zh) * 2022-03-04 2022-06-03 青海省畜牧兽医科学院 基于地理探测器的泡型包虫病环境风险因子分析方法
KR20260049797A (ko) * 2023-07-12 2026-04-14 로이드 트란 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis
WO2025160184A1 (en) * 2024-01-23 2025-07-31 Lloyd Tran Methods for the prophylaxis and treatment of obesity and related conditions and disorders
WO2025179250A1 (en) * 2024-02-25 2025-08-28 Lloyd Tran Methods for the prophylaxis and treatment of autism related disorders
WO2025198995A1 (en) * 2024-03-18 2025-09-25 Lloyd Tran Methods for the prophylaxis and treatment of stroke related disorders
CN119770491B (zh) * 2024-12-20 2025-10-17 北京大学 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2670563B2 (ja) 1988-10-12 1997-10-29 富士通株式会社 半導体装置の製造方法
JP2757960B2 (ja) 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5942422A (en) 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
PT1064256E (pt) 1998-03-17 2004-10-29 Pfizer Prod Inc Biciclo[2.2.1] heptanos e compostos relacionados
US6258582B1 (en) 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
AU781044B2 (en) 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
US6689904B2 (en) 2001-06-29 2004-02-10 Wyeth Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
CA2466701C (en) * 2001-11-13 2013-11-12 Loi Tran Neuroprotective use of cyclic prolyl glycine
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US20050209142A1 (en) * 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
JP4842817B2 (ja) * 2003-09-03 2011-12-21 ニューレン ファーマシューティカルズ リミテッド 神経保護二環式化合物およびその使用方法
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
WO2015013397A2 (en) * 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
JP2021514303A (ja) * 2018-02-19 2021-06-10 ザ マテリアル ワークス，リミテッド 金属薄板デスケーラのための幅及び速度コントロールならびにそれを使用する方法
EP3843768A4 (en) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS

Also Published As

Publication number Publication date
JP7699378B2 (ja) 2025-06-27
WO2019222339A1 (en) 2019-11-21
EP3843768A4 (en) 2022-11-23
US12070458B2 (en) 2024-08-27
BR112020023252A2 (pt) 2021-02-23
JP2021524864A (ja) 2021-09-16
EP3843768A1 (en) 2021-07-07
CN112423774A (zh) 2021-02-26
US20200054629A1 (en) 2020-02-20
AU2019271189A1 (en) 2021-01-07
US11090303B2 (en) 2021-08-17
MA53500A (fr) 2021-08-18
US20220000866A1 (en) 2022-01-06
US20230381175A1 (en) 2023-11-30
JP2025084741A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
GB202015788D0 (en) Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
EP4013403A4 (en) METHODS OF TREATMENT OF PSYCHOLOGICAL AND BRAIN DISORDERS
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
IL279530A (en) Benzodiazepine history, preparations, and methods for the treatment of cognitive disorder
IL292810A (en) Therapeutic compounds and methods of use
IL287280A (en) Compounds and methods for the treatment of ocular disorders
IL291130A (en) Biomarkers and treatments in Alzheimer's disease and mild cognitive impairment
IL276120A (en) Devices and methods for thermal treatment of tissues
EP3952840A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS
EP3973586A4 (en) NEW PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS
EP4054713A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING SKIN DISEASES AND DISORDERS USING LEKTI
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
GB2605422B (en) Treatment of the central nervous system
EP4010347A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN AND ADDICTION DISORDERS
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
SG11202108539XA (en) Compositions comprising amino acids for use and treatment of central nervous system injuries
IL271632A (en) Implant for injured nerve tissue prosthetics, method of surgical treatment for injured nerve tissue and use of porous polytetrafluorethylene
IL278904A (en) Compounds for the treatment of pain, preparations containing them and methods of using them
IL304628A (en) Treatment of skin disorders
PT4031117T (pt) Mutante do ngf para utilização no tratamento ou prevenção de distúrbios oftálmicos
EP3761988A4 (en) Compositions and methods for treating hyperproliferative skin disorders
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
PT3752253T (pt) Composição para prevenção e tratamento de distúrbios do crescimento capilar
AU2021337864A9 (en) Cellular composition for treatment of diseases, disorders or conditions and method of use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)